COST ANALYSIS OF IMPLEMENTING EXPANDED UMBILICAL CORD BLOOD GRAFT IN CANADA
Author(s)
Tremblay G1, Cohen S2, Roy J2
1Adelphi Values, Boston, MA, USA, 2Maisonneuvre-Rosemont Hospital, Montreal, QC, Canada
Presentation Documents
OBJECTIVES: Umbilical cord blood graft (CBG) is an option for hematopoietic stem cell transplantation (HSCT) where bone marrow or peripheral stem-cell transplant (BM/PB) is not possible. Compared to traditional CBG, expanded CBG (ECBG) improves survival and clinical outcomes including median times to platelet and absolute neutrophil count engraftment, chronic and acute graft-versus-host disease (GvHD) and relapse rate. We assessed the costs and cost-effectiveness from the societal perspective of implementing ECBG in Canada. METHODS: Economic and epidemiologic models were developed using the results of a literature review and hospital data analysis, and included direct and indirect costs (e.g. productivity costs). We compared (1) BM/PB with unrelated donors (UD), (2) double umbilical cord blood graft (DUCB), (3) expanded umbilical cord blood graft (EUCB) with one or two cords (optimistic and conservative scenarios) in patients without an option for matched-related donors. RESULTS: Total treatment (direct) costs comprised bone marrow and cord procurement (18-36%), donor search (16-19%), hospitalization (14-18%), and pharmacy (10-14%). DUCB costs were the highest of the different options, totalling $210,000, followed by EUCB (conservative; $206,000, optimistic; $174,000) and UD ($172,000). Adding indirect costs totaled DUCB $400,000, UD $376,000 and EUCB conservative $376,000; optimistic $343,000 (Canadian dollars). Rate of GvHD had the largest impact on indirect costs through preventing return to work (lower productivity). The ICER using the direct costs only for EUCB vs UD was $500 (optimistic) to $7300 (conservative) per QALY. When the societal costs are accounted for, EUCB is an economically dominant treatment option. CONCLUSIONS: When comparing direct costs EUCB is less expensive for the healthcare system than DUCB, but more expensive than UD. When comparing overall societal costs including direct and indirect costs EUCB was least expensive, likely due to lower rate of GvHD.
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PSY20
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Work & Home Productivity - Indirect Costs
Disease
Systemic Disorders/Conditions